Exametazime

Summary

Exametazime (CHEMBL2218892) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 272.39 Da · C13H28N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2218892
Name	Exametazime
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9820753
Molecular formula	C13H28N4O2
Molecular weight	272.39
InChIKey	BPNZYADGDZPRTK-MAEUFBSDSA-N

SMILES: CC(NCC(CNC(/C(=N/O)/C)C)(C)C)/C(=N/O)/C

IUPAC name: (NE)-N-[3-[[3-[[(3E)-3-hydroxyiminobutan-2-yl]amino]-2,2-dimethylpropyl]amino]butan-2-ylidene]hydroxylamine

Also known as: DL HM-PAO, DL-HM-PAO, Exametazima, Exametazime, Hexametazine, EXAMETAZIME

Patent coverage: 4 distinct patent families (8 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).